GlassScriptPhysician profile
Selvi Lingam
NPI 1740296466
$3,903.57
in general payments reported to CMS, 2019-2025
40 companies · $1,019 in 2025
The $1,019 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $105 · 2021: $129 · 2022: $313 · 2023: $242 · 2024: $1,727 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,739 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,739.22 |
| Education | $249.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $359.24 | 2021-2025 | |
| Genentech USA, INC. | $281.00 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $249.19 | 2022-2025 | Enhertu, Tagrisso, Imfinzi |
| Seagen INC. | $229.36 | 2021-2025 | |
| Tempus Ai, INC | $224.46 | 2024 | Xt Cdx |
| Myriad Genetic Laboratories, INC. | $205.55 | 2023-2024 | Myrisk |
| Aveo Pharmaceuticals, INC. | $195.55 | 2024-2025 | |
| Incyte Corporation | $171.65 | 2024-2025 | Jakafi, Monjuvi |
| Celgene Corporation | $158.52 | 2024-2025 | Reblozyl, Sotyktu, Opdivo |
| Glaxosmithkline, LLC. | $148.02 | 2022-2025 | Zejula, Jemperli |
| Puma Biotechnology, INC. | $142.06 | 2019-2024 | |
| Janssen Biotech, INC. | $135.24 | 2022-2025 | Rybrevant, Erleada, Talvey |
| Merck Sharp & Dohme LLC | $119.86 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| Array Biopharma INC | $97.45 | 2019-2024 | Braftovi, Mektovi, Lorbrena |
| Astellas Pharma US INC | $77.31 | 2024-2025 | Xospata, Vyloy, Padcev |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $76.40 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $72.28 | 2024-2025 | |
| Taiho Oncology, INC. | $72.19 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $69.69 | 2024-2025 | Monoferric |
| Eisai INC. | $68.25 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $59.74 | 2021-2025 | Opdivo |
| Alexion Pharmaceuticals, INC. | $59.52 | 2024 | Ultomiris |
| Sobi, INC | $55.28 | 2024 | |
| Daiichi Sankyo INC. | $55.22 | 2024-2025 | Enhertu |
| Janssen Pharmaceuticals, INC | $51.31 | 2023-2024 | Xarelto, Darzalex, Tecvayli |
| Emd Serono, INC. | $48.55 | 2019-2024 | |
| Stemline Therapeutics INC. | $48.32 | 2023-2024 | Orserdu |
| Mirati Therapeutics, INC. | $44.97 | 2023-2024 | Krazati |
| Regeneron Healthcare Solutions, INC. | $44.08 | 2024-2025 | Libtayo, Lynozyfic |
| Lilly USA, LLC | $40.62 | 2025 | Jaypirca, Verzenio |
| Genzyme Corporation | $40.59 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.78 | 2025 | |
| Pharmaessentia USA Corporation | $31.27 | 2024 | Besremi |
| Genmab U.S., INC. | $25.50 | 2025 | Tivdak |
| Sumitomo Pharma America, INC. | $23.79 | 2024 | Orgovyx |
| Ipsen Biopharmaceuticals, INC | $21.97 | 2024 | Onivyde, Somatuline Depot |
| Abbvie INC. | $20.71 | 2025 | |
| Alcresta Therapeutics, INC. | $19.04 | 2024 | Relizorb |
| Janssen Scientific Affairs, LLC | $13.95 | 2025 | Talvey, Tecvayli |
| Pharmacyclics LLC, An Abbvie Company | $13.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Selvi Lingam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.